Wensheng S. Liu

Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 54 publications

ASO Visual Abstract: Complete Segmental Parenchymal Vascular Occlusion for Robotic Enucleation of Distal Pancreatic Tumors (with video).

ASO Visual Abstract: Complete Segmental Parenchymal Vascular Occlusion for Robotic Enucleation of Distal Pancreatic Tumors (with video).

Journal: Annals of surgical oncology

Published: June 15, 2026

Exploring the optimal regimen in advanced hepatocellular carcinoma: a protocol of individual patient data network meta-analysis of randomized controlled trials.

Exploring the optimal regimen in advanced hepatocellular carcinoma: a protocol of individual patient data network meta-analysis of randomized controlled trials.

Journal: Frontiers in immunology

Published: February 05, 2026

Complete Segmental Parenchymal Vascular Occlusion for Robotic Enucleation of Distal Pancreatic Tumors (with video).

Complete Segmental Parenchymal Vascular Occlusion for Robotic Enucleation of Distal Pancreatic Tumors (with video).

Journal: Annals of surgical oncology

Published: December 23, 2025

Pharmacovigilance insights into drug-induced hypercalcemia: evidence from the U.S. FDA Adverse Event Reporting System (FAERS) database.

Pharmacovigilance insights into drug-induced hypercalcemia: evidence from the U.S. FDA Adverse Event Reporting System (FAERS) database.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: November 26, 2025

Unveiling the hidden cardiovascular risk of sipuleucel-T: a pharmacovigilance analysis using the FDA Adverse Event Reporting System, 2010-2025.

Unveiling the hidden cardiovascular risk of sipuleucel-T: a pharmacovigilance analysis using the FDA Adverse Event Reporting System, 2010-2025.

Journal: Frontiers in immunology

Published: September 30, 2025

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.

Journal: Cancer

Published: September 29, 2025

Diagnostic Performance of 68 Ga-SSTR PET/CT and Contrast-Enhanced CT for Preoperative Lymph Node Staging in Duodenal and Pancreatic Neuroendocrine Neoplasms (DP-NENs): A Pathology-Validated Analysis.

Diagnostic Performance of 68 Ga-SSTR PET/CT and Contrast-Enhanced CT for Preoperative Lymph Node Staging in Duodenal and Pancreatic Neuroendocrine Neoplasms (DP-NENs): A Pathology-Validated Analysis.

Journal: Pancreas

Published: July 25, 2025

Emerging causes of anticancer therapies-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: evidence from disproportionality analysis of the FDA adverse event reporting system.

Emerging causes of anticancer therapies-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: evidence from disproportionality analysis of the FDA adverse event reporting system.

Journal: Frontiers in immunology

Published: July 07, 2025

Efficacy and safety of biosimilar trastuzumab (HLX02) in patients with HER2-positive advanced breast cancer: a retrospective real-world analysis.

Efficacy and safety of biosimilar trastuzumab (HLX02) in patients with HER2-positive advanced breast cancer: a retrospective real-world analysis.

Journal: Frontiers in oncology

Published: May 04, 2025

Main pancreatic duct exposure, repair, or reconstruction during minimally invasive pancreatic enucleation: a long-term metabolic outcome from a prospective cohort study (CSPAC-MIEN-1).

Main pancreatic duct exposure, repair, or reconstruction during minimally invasive pancreatic enucleation: a long-term metabolic outcome from a prospective cohort study (CSPAC-MIEN-1).

Journal: International journal of surgery (London, England)

Published: March 10, 2025

Predictive model and novel classification of pancreatic fistula following minimally invasive enucleation: a prospective cohort study (CSPAC-MIEN-2).

Predictive model and novel classification of pancreatic fistula following minimally invasive enucleation: a prospective cohort study (CSPAC-MIEN-2).

Journal: International journal of surgery (London, England)

Published: February 24, 2025

Emerging cardiovascular toxicity associated with CDK4/6 inhibitors: real-world insights from the FDA adverse event reporting system.

Emerging cardiovascular toxicity associated with CDK4/6 inhibitors: real-world insights from the FDA adverse event reporting system.

Journal: Frontiers in pharmacology

Published: January 30, 2025

Showing 1-12 of 54

Last Updated: 09/26/2026